Research-grade material. A Janoshik report for this compound is available on request. For research use only.
An Engineered Variant, Built for a Specific Job
IGF-1 LR3, or Long R3 IGF-1, is not a naturally occurring molecule. It is a deliberately engineered analog of insulin-like growth factor 1 (IGF-1), built by researchers to solve a specific problem that has nothing to do with human physiology: how to keep a growth factor active and available inside a lab dish.
The engineering is precise. Native human IGF-1 is 70 amino acids long. LR3 carries two defined changes: an arginine substituted for glutamic acid at position 3, and a 13-amino-acid extension added to the N-terminus, bringing the total to 83 amino acids. Both changes exist for one reason, to sharply reduce the molecule’s affinity for the IGF binding proteins (IGFBPs) that normally regulate IGF-1 in circulation and in tissue, while leaving its affinity for the type 1 IGF receptor largely intact.
Why That Engineering Matters Only in a Specific Context
In a living organism, native IGF-1 is tightly bound and regulated by IGFBPs, which control how much free IGF-1 is available to bind receptors at any given time. In a cell culture dish, that regulation becomes a laboratory inconvenience rather than a biological safeguard. Researchers working with serum-free or low-serum culture systems found that adding native IGF-1 to a culture often meant most of it was immediately absorbed by IGFBPs present in the system, leaving little available to actually signal through the IGF-1 receptor on the cultured cells.
LR3 was engineered specifically to route around that problem. Because it binds IGFBPs far more weakly, more of it stays available to interact with the type 1 IGF receptor on cells in culture. This is the documented, well-established use of LR3 in the published and technical literature: a growth factor supplement for serum-free and low-serum cell culture, used to support cell proliferation and survival, and applied in research and industrial settings including recombinant protein production in CHO (Chinese hamster ovary) cell lines.
What This Kind of Evidence Is, and Is Not
This is the part that needs to be stated plainly, because it is easy to blur.
LR3’s evidence base is laboratory and cell-culture research. It describes what happens when the molecule is added to cells growing in a dish, and how it behaves at the IGF-1 receptor in that setting. That is a real, well-documented, and useful body of research. It is also a categorically different kind of evidence than a human or animal trial. Cell-culture research can establish what a molecule does at a receptor, in isolated cells, under controlled laboratory conditions. It cannot establish what happens when that molecule is introduced into a whole organism, where absorption, distribution, systemic IGFBP regulation, and organ-level feedback all apply in ways a culture dish does not model.
IGF-1 itself, the native molecule, has an extensive separate literature covering growth signaling, metabolism, and development in whole organisms. That literature belongs to IGF-1. It is not evidence for LR3 specifically, and reading it onto LR3 would misrepresent what has actually been studied for this particular engineered analog.
What the Research Does Not Establish
Read this part twice. The honest limits matter more than the headlines.
- LR3 has no published human trial history. Its research record is laboratory and cell-culture work, not clinical research.
- Cell-culture findings describe receptor-level behavior in isolated cells. They are not a basis for inferring an effect in a whole organism, human or otherwise.
- The literature on LR3’s reduced IGFBP binding and receptor bioavailability comes from cell-culture and industrial bioprocessing contexts (recombinant protein production), not from any study of physiological outcomes.
- This page is a research summary only. It does not say the compound does anything “for you.”
Further Reading
For the full literature review, including the rat and guinea-pig trial data, see IGF-1 LR3: What the Research Actually Shows.
Where This Material Stands
We have not found another vendor in this category stating this distinction as plainly: that LR3’s documented use is a cell-culture reagent, not a studied physiological agent. IGF-1 LR3 is a new addition to Etched’s research catalog. Where an independent laboratory report exists for a compound, the measurements are published on the COA page, including the compounds we hold no report for.
Buyer-intent tag
Cell-culture research / Growth factor signaling
Research Use Only. IGF-1 LR3 (Long R3 IGF-1) is supplied for research use only and is not for human consumption, diagnosis, treatment, or any clinical or therapeutic application. This material is intended solely for use by qualified researchers in controlled laboratory settings. Nothing in this article describes a property the compound delivers or constitutes a recommendation for use in humans. The research referenced above is laboratory and cell-culture research and does not describe outcomes in any whole organism.
Research-grade material. A Janoshik report for this compound is available on request. For research use only.
For Research Use Only. Not for human consumption. Etched Research supplies compounds for laboratory and research use only. Nothing on this page is medical advice, a health claim, or a recommendation to use.